BioSpace News Archive

Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that topline data of the recently completed L-DOS47 dose escalation study in combination with pemetrexed and carboplatin in recurrent or metastatic non-squamous non-small cell lung cancer (“LDOS001”) will be published at the ASCO 2020 Annual Conference. The A

- Upfront payment of $50m received from Astellas and approximately $90m offering completed - - Financial guidance confirmed: funded into 2H 2021 - - Orphan Drug Designation positive opinion for ADP-A2M4 in the EU adds to US FDA ODD and RMAT designations - - Upcoming presentations at major scientific meetings with data from ADP-A2M4, ADP-A2AFP, and allogeneic programs - - Conference call to be held today at 8:00 a.m. EDT (1:00 p.m. BST) - PHILADELPHIA and OXFORDSHIRE, United Kin

Seevix Material Sciences Ltd., which develops and manufactures synthetic SVX™ spidersilk, announced that ASICS Ventures Corporation has invested in Seevix.

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today reported financial results for the third quar

Inozyme Pharma, Inc. , a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization impacting the vasculature, soft tissue and skeleton, and GACI Global ( www.gaciglobal.org ), a patient advocacy organization dedicated to bettering the lives of families affected by Generalized Arterial Calcification of Infancy and/or Autosomal Recessive Hypophosphatemic Rickets Type 2 (GACI/A

Endo International plc (the “Company”) (NASDAQ:ENDP) announced today that its wholly owned subsidiaries, Par Pharmaceutical, Inc., a New York corporation (“PPI”), Endo Designated Activity Company, a designated activity company incorporated under the laws of Ireland (“Endo DAC”), Endo Finance LLC, a Delaware limited liability company (“End

Millar, Inc., medical device manufacturer and OEM solutions provider, is pleased to announce the launch of its new Millar.com website design.

Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 2020 RBC Capital Markets Global Healthcare Conference

KB105 was well tolerated with no adverse events or immune response following redosing Clearly detectable TGM-1 expression in all treated areas following initial and repeat administration. KB105-expressed TGM1 was correctly localized in the epidermis, co-localizing with loricrin, and was functionally active Phenotypic evaluation of KB105 treated areas showed reduced reversion to ichthyotic scaling phenotype Amy Paller, M.D., Professor and Chair of Dermatology at Northwestern University

SANANBIO, an industry-leading indoor farming solution provider, and Hode AgTech, agri-technologies developer and promoter, announced their partnership on indoor farming projects on the 13th of May, 2020.